Firms ally to develop deuterium-based drugs for cancer, inflammation

Concert Pharmaceuticals granted Celgene the right to use its deuterated chemical entity technology to develop new deuterium-modified small compounds for cancer and inflammation. Concert will get an upfront payment and more than $300 million in possible milestone fees for each program selected for development, plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID